Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for ZLDPF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 34.81M
March 31, 2026 -18.17M
December 31, 2025 -56.83M
September 30, 2025 -138.71M
June 30, 2025 -233.14M
March 31, 2025 78.25M
December 31, 2024 53.25M
September 30, 2024 -894.48M
June 30, 2024 -4.391M
March 31, 2024 -200.66M
December 31, 2023 0.9658M
September 30, 2023 23.38M
June 30, 2023 -174.73M
March 31, 2023 -9.348M
December 31, 2022 14.08M
September 30, 2022 10.44M
June 30, 2022 -29.84M
March 31, 2022 44.36M
December 31, 2021 -1.793M
September 30, 2021 -0.3355M
June 30, 2021 0.1259M
March 31, 2021 -0.7819M
December 31, 2020 0.6394M
September 30, 2020 -2.256M
June 30, 2020 -24.77M
Date Value
March 31, 2020 -2.757M
December 31, 2019 -0.6061M
September 30, 2019 -2.771M
June 30, 2019 -0.0274M
March 31, 2019 -4.514M
December 31, 2018 -72.22M
September 30, 2018 211.53M
June 30, 2018 -0.1604M
March 31, 2018 -0.0959M
December 31, 2017 -13.73M
September 30, 2017 2.796M
June 30, 2017 1.465M
March 31, 2017 44.48M
December 31, 2016 19.58M
September 30, 2016 -3.299M
June 30, 2016 -4.017M
March 31, 2016 -13.35M
December 31, 2015 -0.1108M
September 30, 2015 -0.2239M
June 30, 2015 -0.2016M
March 31, 2015 -0.0596M
December 31, 2014 -0.2723M
September 30, 2014 -0.1577M
June 30, 2014 -0.0649M
March 31, 2014 4.154M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Genmab A/S 2.026M
Ascendis Pharma A/S -3.268M
Bavarian Nordic A/S -5.386M
Evaxion AS --
ACADIA Pharmaceuticals, Inc. -8.529M